What are best practices for dermatologists and oncologists to collaborate in order to optimize multidisciplinary care of patients with high risk CSCC?

I find the biggest gains come from having clear and consistent communication around patient identification and treatment planning. Aligning on what constitutes “high risk” — both for local recurrence and metastasis — and which patients truly fall into the very-high-risk category is essential. It’s c...

A network of specialists familiar with cSCC is necessary to optimize care that is tailored and appropriate for each unique case. Avoiding under-treatment and over-treatment is important, but also challenging, given the high volume of cSCC tumors with variable patterns of presentation and numerous cr...

In recent years, there has been a notable advancement in our ability to risk-stratify patients with cutaneous squamous cell carcinoma (CSCC). In addition to the classic staging systems, we can now sub-stratify those stages, run propensity score analyses (RISCC and Erasmus MC models), and look at gen...